The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10434 malaria professionals are enjoying the free benefits of MalariaWorld today

efficacy in patients

NOT Open Access | Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria

May 21, 2020 - 06:50 -- NOT Open Access
Author(s): 
St Jean PL, Koh GCKW, Green JA, et al.
Reference: 
Pharmacogenet Genomics. 2020 May 19

Plasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was the 8-aminoquinoline, primaquine, requiring daily treatment for 14 days. Tafenoquine, an 8-aminoquinoline single-dose treatment with activity against P. vivax hypnozoites, has recently been approved by the US Food and Drug Administration and Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria in patients 16 years and older.

Subscribe to RSS - efficacy in patients